MARLOTAMIG
UNII 02Z59O1UOM

Substance Identification & Data

This profile provides standardized clinical and technical data for Marlotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 02Z59O1UOM.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2765077-69-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

02Z59O1UOM

CAS Registry Number

2765077-69-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MARLOTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178284

National Cancer Institute reference terminology for clinical and research data.

INN ID

13010

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-18

Identifier assigned by the United States Adopted Names Council.

Substance Type

Marlotamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Marlotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Marlotamig

Common Names & Synonyms

Dalmitamig

Immunoglobulin G4 [230-proline,235-proline,236-valine,237-alanine,de-238-glycine,436-arginine,437-phenylalanine,446-proline], anti-(human CD28 antigen) (human monoclonal REGN7075 γ4-chain), disulfide with human monoclonal REGN7075 κ-chain, (228→227′),(231→230′)-bis(disulfide) with immunoglobulin G4 [229-proline,234-proline,235-valine,236-alanine,de-237-glycine] anti-(human epidermal growth factor receptor) (human monoclonal REGN7075 γ4-chain) disulfide with human monoclonal REGN7075 κ-chain

MARLOTAMIG [USAN]

REGN 7075 [WHO-DD]

immunoglobulin G4-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[Homo sapiens CD28 (T cell specific surface glycoprotein CD28, TP44)], Homo sapiens monoclonal antibody, bispecific, bivalent; H-gamma4 heavy chain anti-EGFR Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (92.8%) -(IGHD) -IGHJ3*01 (92.3%) M123>T (116), CDR-IMGT [8.7.15] (26-33.51-57.96-110)) (1-121) -Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92, G4v7 CH2 delE1.4, P1.3, V1.2, A1.1 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 E1.4>del, F1.3>P (234), L1.2>V (235), G1.1>A (236), L92 (312) (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-215')-disulfide with L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')]; H-gamma4 heavy chain anti-CD28 Homo sapiens (1''-448'') [VH (Homo sapiens IGHV4-59*01 (96.9%) -(IGHD) -IGHJ6*01 (100%), CDR-IMGT [8.7.16] (26''-33''.51''-57''.96''-111'')) (1''-122'') -Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92, G4v7 CH2 delE1.4, P1.3, V1.2, A1.1, G4v8 CH3 R115, F116, P125 (CH1 (123''-220''), hinge 1-12 S10>P (230'') (221''-232''), CH2 E1.4>del, F1.3>P (235''), L1.2>V (236''), G1.1>A (237''), L92 (310'') (233''-341''), CH3 H115>R (436''), Y116>F (437''), L125>P (446'') (342''-446''), CHS (447’’-448'')) (123''-448'')], (136''-215''')-disulfide with L-kappa light chain Homo sapiens common (1'''-215''') [V-KAPPA (Homo sapiens IGKV3-20*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27'''-33'''.51'''-53'''.90'''-98''')) (1'''-108''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154'''), V101 (192''') (109'''-215''')]; dimer (227-228'':230-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa

marlotamig [INN]